Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions

Mitchell B. Diccianni, Ayse Batova, John Yu, Thai Vu, Jeanette Pullen, Michael Amylon, Bradley H Pollock, Alice L. Yu

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.

Original languageEnglish (US)
Pages (from-to)549-558
Number of pages10
JournalLeukemia Research
Volume21
Issue number6
DOIs
StatePublished - Jun 1997
Externally publishedYes

Keywords

  • p15
  • p16
  • p18
  • Prognosis
  • Relapse
  • T-ALL

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions'. Together they form a unique fingerprint.

  • Cite this